SCHEMBL5136207

SCHEMBL5136207

CCCCn1c(CN(Cc2ccccc2)Cc2ccc(C)cc2C)cnc1-c1ccccc1

nearest known ligand 0.41

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
TSHR P16473 2/20 0.41
GRIN1 Q05586 2/20 0.37
GRIN2B Q13224 2/20 0.37
C5AR1 P21730 1/20 0.36
HSD11B1 P28845 2/20 0.36
TP53 P04637 1/20 0.34
BRD4 O60885 1/20 0.34
PDE4B Q07343 2/20 0.33
CRHR1 P34998 1/20 0.33
PGR P06401 1/20 0.33
RORA P35398 1/20 0.33
RORC P51449 1/20 0.33
RORB Q92753 1/20 0.33
NR1H3 Q13133 1/20 0.33
ADORA2B P29275 1/20 0.32
KDM4E B2RXH2 1/20 0.32
HSD17B10 Q99714 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5137588 0.93 TSHR (0.41) TSHRC5AR1HSD11B1TP53BRD4
SCHEMBL5136205 0.91 TSHR (0.39) TSHRGRIN1GRIN2BC5AR1HSD11B1
SCHEMBL5136720 0.90 TSHR (0.44) TSHRC5AR1HSD11B1BRD4PDE4B
SCHEMBL5137319 0.88 TSHR (0.47) TSHRC5AR1HSD11B1TP53PDE4B
SCHEMBL5072278 0.88 TSHR (0.51) TSHRC5AR1HSD11B1PDE4BNR1H3
SCHEMBL5135653 0.88 TSHR (0.37) TSHRGRIN1GRIN2BC5AR1TP53
SCHEMBL5136082 0.88 C5AR1 (0.54) TSHRC5AR1TP53KDM4EHSD17B10
SCHEMBL5137098 0.88 TSHR (0.44) TSHRC5AR1HSD11B1TP53PDE4B
SCHEMBL5136036 0.86 TSHR (0.45) TSHRC5AR1HSD11B1TP53PDE4B
SCHEMBL5135313 0.85 TSHR (0.40) TSHRGRIN2BC5AR1HSD11B1TP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1490044-A4 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORP (US) 2008-04-16 EP disclosed
EP-1490044-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2004-12-29 EP disclosed
WO-2003084524-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2003-10-16 WO disclosed